F-Star Therapeutics Inc. (FSTX) Announces Proposed Public Offering of Common Stock
Get Alerts FSTX Hot Sheet
Join SI Premium – FREE
F-star Therapeutics, Inc. (Nasdaq: FSTX) (the “Company” or “F-star”), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that it has commenced an underwritten public offering of its common stock. F-star also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the aggregate number of shares of common stock offered in the public offering on the same terms and conditions. All of the shares of common stock in the offering are to be sold by F-star.
F-star intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, for working capital and general corporate purposes, including, but not limited to, clinical trials, research and development activities and capital expenditures. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
SVB Leerink is acting as sole bookrunning manager for the offering.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tungray Technologies (TRSG) Prices 1.25M Share IPO at $4/sh
- NRx Pharmaceuticals (NRXP) Announces Proposed Share Offering
- Biohaven Pharma (BHVN) Announces Proposed Public Offering of Common Shares
Create E-mail Alert Related Categories
Corporate News, Equity OfferingsRelated Entities
S3Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!